Karyopharm Therapeutics Inc.

KPTI

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001503802

E

weakest fifth of 369 graded peers in healthcare

rank 307 of 369; percentile 83.2; sampling error 2.5 points; lower is stronger


A B C D E

E, the bear




Scoreboard	
Profitability	A percentile 4.3
Solvency	E percentile 92.5
Growth and financing	E percentile 84.9
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $108.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, distress; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 13, 2026 271 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	$0.04 2026-11-10; market equity $834,678; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 13, 2026

We are a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 ("XPO1").

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 4.3						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

a prior annual debt, equity, and cash observation is required						
Accruals ratio	(88.5%)	(6.6%)	4.3	800	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 92.5						
Twelve-month failure probability	63.39%	0.08%	100.0	247	2026-06-30	
Altman Z double-prime	(58.62)	(0.35)	90.3	745	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	1.12x	2.95x	87.3	826	2025-12-31	
Growth and financing, sleeve percentile 84.9						
Revenue growth, three-year compound	(2.4%)	10.1%	76.9	412	2025-12-31	
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(32.9%)	2.2%	93.8	694	2025-12-31	
Net share issuance, one year	118.0%	2.5%	84.1	628	2026-02-05	


Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 118.0%
Distress	CHS probability 63.391737%; universe top-decile threshold 1.836407%
Fortress balance sheet	cash minus debt is 21,166,000 USD; Altman Z is not used

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
302	Lexicon Pharmaceuticals, Inc. (LXRX)	81.8	D/E	fortress balance sheet
303	Moderna, Inc. (MRNA)	82.1	D/E	
304	Accuray Inc. (ARAY)	82.3	D/E	late filer
305	Stereotaxis, Inc. (STXS)	82.6	E	
306	SkinHealth Systems Inc. (SKIN)	82.9	E	
307	Karyopharm Therapeutics Inc. (KPTI)	83.2	E	dilution, distress, fortress balance sheet
308	Opko Health, Inc. (OPK)	83.4	E	fortress balance sheet
309	Amarin Corp. Plc\Uk (AMRN)	83.7	E	fortress balance sheet
310	Outset Medical, Inc. (OM)	84.0	E	dilution
311	Journey Medical Corp. (DERM)	84.2	E	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

312	Novavax Inc. (NVAX)	84.5	E

What the price implies

at the 2026-11-10 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(79.0%)	(1.9%)	6
Distance from 52-week high	(99.8%)	(28.5%)	0
EBIT to enterprise value	(79.1%)	(1.6%)	10
Free cash flow yield	(19,097.3%)	(1.0%)	0
Book value to price	(836.59)	0.27	0
Sales to price	370.11	0.29	100
Composite equity issuance, five years	151.7%	20.8%	85
Relative strength against the sector, log excess return	(1.73)	(0.19)	6

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$55.0M
Operating cash flow, four quarters	-$65.3M
Months of runway	10.1
Days since last periodic filing	90 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	$1.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-$98.3M	2021-12-31	2024-02-29	10-K	24-022650
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$123.8M	2021-12-31	2024-02-29	10-K	24-022650
3	income tax	us-gaap:IncomeTaxExpenseBenefit	$268,000	2021-12-31	2024-02-29	10-K	24-022650
4	total debt	us-gaap:LongTermDebt	$169.3M	2021-12-31	2022-03-01	10-K	22-002548
5	book equity	us-gaap:StockholdersEquity	-$79.7M	2021-12-31	2025-02-19	10-K	25-022765
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$190.5M	2021-12-31	2024-02-29	10-K	24-022650
7	net income	us-gaap:NetIncomeLoss	-$196.0M	2025-12-31	2026-02-13	10-K	26-049397
8	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$75.4M	2025-12-31	2026-02-13	10-K	26-049397
9	assets	us-gaap:Assets	$108.4M	2025-12-31	2026-02-13	10-K	26-049397
10	assets	us-gaap:Assets	$164.4M	2024-12-31	2026-02-13	10-K	26-049397
11	current assets	us-gaap:AssetsCurrent	$103.1M	2025-12-31	2026-02-13	10-K	26-049397
12	current liabilities	us-gaap:LiabilitiesCurrent	$92.1M	2025-12-31	2026-02-13	10-K	26-049397
13	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.8B	2025-12-31	2026-02-13	10-K	26-049397
14	operating income	us-gaap:OperatingIncomeLoss	-$90.7M	2025-12-31	2026-02-13	10-K	26-049397
15	book equity	us-gaap:StockholdersEquity	-$292.9M	2025-12-31	2026-02-13	10-K	26-049397
16	liabilities	us-gaap:Liabilities	$401.3M	2025-12-31	2026-02-13	10-K	26-049397

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

17	depreciation amortization	us-gaap:Depreciation	$789,000	2021-12-31	2024-02-29	10-K	24-022650
18	operating income	us-gaap:OperatingIncomeLoss	-$129.5M	2023-12-31	2026-02-13	10-K	26-049397
19	interest expense	us-gaap:InterestExpense	$23.8M	2023-12-31	2024-02-29	10-K	24-022650
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$146.1M	2025-12-31	2026-02-13	10-K	26-049397
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$145.2M	2024-12-31	2026-02-13	10-K	26-049397
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$146.0M	2023-12-31	2026-02-13	10-K	26-049397
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$157.1M	2022-12-31	2025-02-19	10-K	25-022765
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2025-12-31	2026-02-13	10-K	26-049397
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$127.5M	2024-12-31	2026-02-13	10-K	26-049397
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$142,000	2024-12-31	2026-02-13	10-K	26-049397
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$92.7M	2023-12-31	2026-02-13	10-K	26-049397
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2023-12-31	2026-02-13	10-K	26-049397
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$149.6M	2022-12-31	2025-02-19	10-K	25-022765
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$118,000	2022-12-31	2025-02-19	10-K	25-022765
31	depreciation amortization	us-gaap:Depreciation	$296,000	2025-12-31	2026-02-13	10-K	26-049397
32	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$196.0M	2025-12-31	2026-02-13	10-K	26-049397
33	income tax	us-gaap:IncomeTaxExpenseBenefit	$43,000	2025-12-31	2026-02-13	10-K	26-049397
34	current assets	us-gaap:AssetsCurrent	$156.5M	2024-12-31	2026-02-13	10-K	26-049397
35	current liabilities	us-gaap:LiabilitiesCurrent	$92.3M	2024-12-31	2026-02-13	10-K	26-049397
36	assets	us-gaap:Assets	$240.4M	2023-12-31	2025-02-19	10-K	25-022765
37	assets	us-gaap:Assets	$358.2M	2022-12-31	2024-02-29	10-K	24-022650
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	18,343,968	2026-02-05	2026-02-13	10-K	26-049397
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	126,240,054	2025-02-14	2025-02-19	10-K	25-022765

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.